MaxCyte Signs a Strategic Platform License with Curamys for Cell and Gene Therapies to Treat Rare Intractable Diseases
Shots:
- Curamys to get the non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology (which is used for the production of proteins) and ExPERT platform. MaxCyte will receive platform licensing fees and program-related revenue
- MaxCyte's ExPERT instrument portfolio, an electroporation technology used for complex cell engineering that provides high-end performance to enable biological and cellular therapies
- Curamys' goal is to transform biomedical sciences through the use of cell fusion-based technologies by assisting in the identification of genetic factors underlying a variety of rare diseases with unknown medical causes
Ref: Globenewswire | Image: Compass Therapeutics
Click here to read the full press release